公开(公告)号：US20090312276A1

公开(公告)日：2009-12-17

申请号：US12484104

申请日：2009-06-12

Applicant: Mark Matteucci ,  Photon Rao ,  Jian-Xin Duan

Inventor： Mark Matteucci ,  Photon Rao ,  Jian-Xin Duan

IPC: A61K31/704 ,  A61K31/7048 ,  A61P35/00

CPC classification number: A61K31/415 ,  A61K31/4166 ,  A61K31/44 ,  A61K31/5377 ,  A61K47/54 ,  A61K47/559 ,  A61K47/6899 ,  B82Y5/00

Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.

Abstract translation: 当单独施用或与一种或多种抗肿瘤剂组合时，缺氧活化的前药可用于治疗癌症。

公开(公告)号：US20060258656A1

公开(公告)日：2006-11-16

申请号：US10549545

申请日：2004-03-29

Applicant: Mark Matteucci ,  Photon Rao ,  Jian-Xin Duan

Inventor： Mark Matteucci ,  Photon Rao ,  Jian-Xin Duan

IPC: A61K31/5377 ,  A61K31/4166

CPC classification number: A61K31/415 ,  A61K31/4166 ,  A61K31/44 ,  A61K31/5377 ,  A61K47/54 ,  A61K47/559 ,  A61K47/6899 ,  B82Y5/00

Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.

公开(公告)号：US06989140B2

公开(公告)日：2006-01-24

申请号：US10327226

申请日：2002-12-20

Applicant: George Tidmarsh ,  Mark Matteucci

Inventor： George Tidmarsh ,  Mark Matteucci

IPC: A61K49/00

CPC classification number: A61K49/0052 ,  A61K49/0021 ,  A61K49/0041

Abstract: Methods are provided for cancer and pre-cancer detection by increased uptake of fluorophore glucose or deoxyglucose conjugates in cancerous and pre-cancerous cells relative to normal cells.

公开(公告)号：US06875593B2

公开(公告)日：2005-04-05

申请号：US10294203

申请日：2002-11-14

Applicant: Brian Froehler ,  Rick Wagner ,  Mark Matteucci ,  Robert J. Jones ,  Arnold J. Gutierrez ,  Jeff Pudlo

Inventor： Brian Froehler ,  Rick Wagner ,  Mark Matteucci ,  Robert J. Jones ,  Arnold J. Gutierrez ,  Jeff Pudlo

IPC: C07H19/06 ,  C07H19/10 ,  C07H19/20 ,  C07H21/00 ,  C12Q1/68 ,  H04L12/24 ,  C12P19/34 ,  C07H21/02

CPC classification number: C07H19/06 ,  C07H19/10 ,  C07H19/20 ,  C07H21/00 ,  C12Q1/6839 ,  C12Q2525/101

Abstract: Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention. Compositions of the invention can be used as pharmaceutical agents to treat various diseases such as those caused by viruses and can be used for diagnostic purposes in order to detect viruses or disease conditions.

公开(公告)号：US06683166B2

公开(公告)日：2004-01-27

申请号：US10176763

申请日：2002-06-21

Applicant: Sundaramoorthi Swaminathan ,  Mark Matteucci ,  Jeff Pudlo ,  Robert J. Jones

Inventor： Sundaramoorthi Swaminathan ,  Mark Matteucci ,  Jeff Pudlo ,  Robert J. Jones

IPC: C07H2100

CPC classification number: C12N15/113 ,  C07H19/06 ,  C07H21/00 ,  C12N2310/319 ,  C12Q1/68

Abstract: The invention relates to novel modified oligonucleotides, the construction thereof, and their use in oligonucleotide-based therapies. More specifically, the invention is to novel oligonucleotides having modified internucleoside linkages which are resistant to nucleases, having enhanced ability to penetrate cells, and which are capable of binding target oligonucleotide sequences in vitro and in vivo. The modified oligonucleotides of the invention are particularly useful in oligonucleotide-based therapies utilizing the modified oligonucleotides to interrupt protein synthesis or transcription or to otherwise inactivate messenger RNA or double stranded DNA.

Abstract translation: 本发明涉及新型修饰的寡核苷酸，其构建及其在基于寡核苷酸的疗法中的应用。 更具体地，本发明是具有对核酸酶具有抗性的具有修饰的核苷间键的具有增强的穿透细胞的能力并且能够在体外和体内结合靶寡核苷酸序列的新型寡核苷酸。 本发明的经修饰的寡核苷酸特别可用于使用经修饰的寡核苷酸中断蛋白质合成或转录或以其它方式灭活信使RNA或双链DNA的基于寡核苷酸的治疗。

公开(公告)号：US5792847A

公开(公告)日：1998-08-11

申请号：US467422

申请日：1995-06-06

Applicant: Chris A. Buhr ,  Mark Matteucci

Inventor： Chris A. Buhr ,  Mark Matteucci

IPC: A61K31/70 ,  A61K48/00 ,  C07H19/04 ,  C07H19/06 ,  C07H19/10 ,  C07H19/16 ,  C07H19/20 ,  C07H21/00 ,  C12N15/09 ,  C12N15/113 ,  C07H31/70

CPC classification number: C12N15/113 ,  C07H19/04 ,  C07H19/06 ,  C07H19/10 ,  C07H19/16 ,  C07H19/20 ,  C07H21/00 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3517 ,  C12N2310/3527 ,  C12N2310/353 ,  C12N2310/3535

Abstract: Oligomers which have substituents on the 2' position are resistant to oligonucleases and furthermore can be derivatized to deliver reagents or drugs, to carry label, or to provide other properties.

Abstract translation: 在2'位上具有取代基的低聚体对寡核苷酸具有抗性，此外可衍生化以递送试剂或药物，携带标签或提供其它性质。

公开(公告)号：US08507464B2

公开(公告)日：2013-08-13

申请号：US13163303

申请日：2011-06-17

Applicant: Mark Matteucci ,  Jian-Xin Duan ,  Hailong Jiao ,  Jacob Kaizerman

Inventor： Mark Matteucci ,  Jian-Xin Duan ,  Hailong Jiao ,  Jacob Kaizerman

IPC: A61K31/675 ,  A61K31/665 ,  A61K31/67 ,  A61K31/664 ,  C07F9/655 ,  C07F9/6506 ,  C07F9/6553 ,  C07F9/24 ,  A61P35/00

CPC classification number: A61K31/675 ,  A61K31/337 ,  A61K31/513 ,  A61K31/7068 ,  A61K33/24 ,  C07F9/6506 ,  C07F9/65397

Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.

Abstract translation: 当单独施用或与一种或多种抗肿瘤剂组合时，氨基磷酸烷基酯前体药物可用于治疗癌症。

公开(公告)号：US08309554B2

公开(公告)日：2012-11-13

申请号：US12992261

申请日：2009-05-14

Applicant: Jason Lewis ,  Mark Matteucci ,  Tao Chen ,  Hailong Jiao

Inventor： Jason Lewis ,  Mark Matteucci ,  Tao Chen ,  Hailong Jiao

IPC: A61K31/496 ,  A61K31/437 ,  A61K31/4436 ,  A61K31/4192 ,  A61K31/4178 ,  A61K31/4168 ,  A61K31/381 ,  C07D409/02 ,  C07D471/02 ,  C07D409/06 ,  C07D233/54 ,  C07D333/42

CPC classification number: C07D333/42

Abstract: Hypoxia activated drug compounds having a structure of formula (I) are useful in the treatment of cancer and other hyperproliferative diseases.

Abstract translation: 具有式（I）结构的缺氧活化药物化合物可用于治疗癌症和其它过度增生性疾病。

公开(公告)号：US20110190310A1

公开(公告)日：2011-08-04

申请号：US12992261

申请日：2009-05-14

Applicant: Jason Lewis ,  Mark Matteucci ,  Tao Chen ,  Hailong Jiao

Inventor： Jason Lewis ,  Mark Matteucci ,  Tao Chen ,  Hailong Jiao

IPC: A61K31/496 ,  C07D233/54 ,  A61K31/4168 ,  C07D333/42 ,  A61K31/381 ,  C07D409/06 ,  A61K31/4436 ,  A61K31/4178 ,  C07D471/02 ,  A61K31/437 ,  C07D409/02 ,  A61K31/4192 ,  A61P35/00

CPC classification number: C07D333/42

Abstract: Hypoxia activated drug compounds having a structure of formula (I) are useful in the treatment of cancer and other hyperproliferative diseases.

Abstract translation: 具有式（I）结构的缺氧活化药物化合物可用于治疗癌症和其它过度增生性疾病。

公开(公告)号：US20080214576A1

公开(公告)日：2008-09-04

申请号：US11791197

申请日：2005-11-27

Applicant: Mark Matteucci ,  Jian-Xin Duan ,  Photon Rao

Inventor： Mark Matteucci ,  Jian-Xin Duan ,  Photon Rao

IPC: A61K31/519 ,  C07D491/147 ,  C07D221/18 ,  A61P35/00 ,  A61K31/4365 ,  A61K31/437 ,  C07D495/04

CPC classification number: C07D471/04 ,  C07D221/18 ,  C07D487/04 ,  C07D491/147 ,  C07D495/04

Abstract: Compositions and methods for treating cancer and other hyperproliferatice disease conditions with topoisomerase inhibitors and their prodrugs are disclosed.

Abstract translation: 公开了用拓扑异构酶抑制剂及其前体药物治疗癌症和其它过度增生症病症的组合物和方法。